Compare Raytheon Technologies Corp (RTX) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Raytheon Technologies Corp trades at $184.95 (market cap $242.95B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Raytheon Technologies Corp is far larger — about 106.6× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.62% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| RTX | SLS | |
|---|---|---|
Market Cap | $242.95B | $2.28B |
Volume | 4,213,378 | 3,128,960 |
Sector | Industrials | Health |
52-Week High | $225.49 | $15.46 |
52-Week Low | $157.00 | $1.39 |
Typical Hold Time | 78 Days | — |
Enterprise Value | $273.50B | $2.15B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
